Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEBOA Trial
NCT07429760Enrolling by invitation
- Sponsor
- Shaukat Khanum Memorial Cancer Hospital & Research Centre
- Start
- Aug 2025
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of rifaximin and metronidazole in colorectal cancer (CRC) (2 arms), sponsored by Shaukat Khanum Memorial Cancer Hospital & Research Centre. Primary endpoint: Surgical Site Infection at 30 days. Started Aug 2025; status: enrolling by invitation.
02
Drugs
rifaximinmetronidazole
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07429760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07429760.